Monitor for IND submission timing and any financing events (dilutive offering likely given $4M cash burn). The cancer cachexia expansion is early-stage and non-catalytic.
Price Chart
Executive Summary
Curanex Pharmaceuticals provided a Q1 2026 business update focused on preclinical progress for its lead candidate Phyto-N (ulcerative colitis), including completion of GMP pilot-scale manufacturing and a dose-range finding toxicology study with no adverse findings. The company also expanded its pipeline strategy to include cancer cachexia. With only $4.0M in cash and no revenue, the filing is a routine development-stage update with no financial results or guidance — the stock's $9M market cap and historical negative drift suggest limited near-term catalyst impact.
Key Facts
- Completed GMP pilot-scale batch of Phyto-N in February 2026
- Completed 28-day dose-range finding toxicology study with no treatment-related adverse findings
- Expanded pipeline to include cancer cachexia as a new core indication
- Cash and cash equivalents of $4.0M as of March 31, 2026
- Planned IND submission for ulcerative colitis in Q4 2026
- No revenue reported; pre-revenue clinical-stage biotech
Financial Impact
No revenue or earnings reported; cash position of $4.0M provides runway for IND-enabling activities but limited capital for extended operations
Risk Factors
- Cash runway limited to $4.0M — likely need for dilutive financing before Q4 2026 IND
- Pre-revenue stage with no approved products; regulatory and clinical failure risk
- Historical negative drift on CURX filings suggests limited market interest in development updates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $4.77 | awaiting T+20 | — | $4.75 (−0.31%) |
Aug 17, 2026 10w ago | 8-K | $4.44 $4.37 | ▼ −1.69% | ▼ −0.70% | $4.75 (+6.98%) |
May 14, 2026 23w ago | 8-K | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.75 (+1417.57%) |
May 14, 2026 23w ago | Press Release | $0.3130 $0.3210 | ▲ +2.56% | ▲ +3.41% | $4.75 (+1417.57%) |
May 7, 2026 24w ago | 8-K | $0.3160 $0.3260 | ▲ +3.16% | ▲ +0.03% | $4.75 (+1403.16%) |
Apr 2, 2026 29w ago | 8-K | $0.4900 $0.4170 | ▼ −14.90% | ▼ −24.77% | $4.75 (+869.39%) |
Mar 30, 2026 30w ago | Press Release | $0.5110 $0.4300 | ▼ −15.85% | ▼ −25.27% | $4.75 (+829.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers